Related Experiment Videos
Serum beta-2 microglobulin in chronic lymphocytic leukaemia
Acta Medica Hungarica
|January 1, 1985
Summary
Serum beta-2-microglobulin levels correlate with lymphocyte count in chronic lymphocellular leukemia. This finding suggests beta-2-microglobulin is a reliable indicator for monitoring therapy effectiveness in advanced stages.
Area of Science:
- Hematology
- Oncology
- Clinical Chemistry
Background:
- Chronic lymphocellular leukemia (CLL) is a lymphoid malignancy.
- Staging systems like the Rai classification are crucial for prognosis.
- Biomarkers are needed for effective monitoring of CLL.
Purpose of the Study:
- To investigate the relationship between serum beta-2-microglobulin and clinical parameters in CLL.
- To determine if serum beta-2-microglobulin can serve as a reliable indicator for therapy monitoring in advanced CLL.
Main Methods:
- Radioimmunoassay was used to measure serum beta-2-microglobulin levels.
- 25 patients with chronic lymphocellular leukemia (stages III-IV) were included.
- Correlation analysis was performed between beta-2-microglobulin and absolute lymphocyte count/organ infiltration score.
Main Results:
- A significant positive correlation was observed between absolute lymphocyte count and serum beta-2-microglobulin.
- No significant correlation was found between organ infiltration score and serum beta-2-microglobulin.
- Increased beta-2-microglobulin production is primarily attributed to circulating lymphocytes.
Conclusions:
- Serum beta-2-microglobulin is significantly associated with lymphocyte count in advanced CLL.
- The radioimmunoassay for beta-2-microglobulin is a reliable tool for monitoring CLL progression and therapeutic response.
- This biomarker aids in evaluating treatment efficacy in chronic lymphocellular leukemia patients.